1. From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies
- Author
-
Ilaria Guadagni and M.C. Fantini
- Subjects
Oncology ,medicine.medical_specialty ,Carcinogenesis ,Colorectal cancer ,Population ,Inflammation ,Disease ,digestive system ,Inflammatory bowel disease ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Animals ,Humans ,Medicine ,Colitis ,education ,education.field_of_study ,Hepatology ,business.industry ,Gastroenterology ,nutritional and metabolic diseases ,Cancer ,medicine.disease ,Ulcerative colitis ,digestive system diseases ,Gastrointestinal Microbiome ,Causality ,030220 oncology & carcinogenesis ,Disease Progression ,Colitis, Ulcerative ,030211 gastroenterology & hepatology ,Colitis-Associated Neoplasms ,medicine.symptom ,business ,Signal Transduction - Abstract
The risk of colorectal cancer (CRC) is higher in patients with inflammatory bowel disease (IBD). Population-based data from patients with ulcerative colitis (UC) estimate that the risk of CRC is approximately 2- to 3-fold that of the general population; patients with Crohn's disease appear to have a similar increased risk. However, the true extent of colitis-associated cancer (CAC) in undertreated IBD is unclear. Data suggest that the size (i.e., severity and extent) and persistence of the inflammatory process is largely responsible for the development of CRC in IBD. As patients with IBD and CRC have a worse prognosis than those without a history of IBD, the impact of current therapies for IBD on CAC is of importance. Chronic inflammation of the gut has been shown to increase the risk of developing CAC in both UC and CD. Therefore, control of inflammation is pivotal to the prevention of CAC. This review presents an overview of the current knowledge of CAC in IBD patients, focusing on the role of inflammation in the pathogenesis of CAC and the potential for IBD drugs to interfere with the process of carcinogenesis by reducing the inflammatory process or by modulating pathways directly involved in carcinogenesis.
- Published
- 2021